This study characterized the induction of the rat hepatic
cytochrome P-450-dependent
mixed function oxidase system by
SK&F 86002 [6-(4'-fluorophenyl)-5-(4'-pyridyl)-2,3-dihydroimidazo-(2,1-b)thia zole], an inhibitor of both the
cyclooxygenase and
5-lipoxygenase pathways of
arachidonic acid metabolism. The induction characteristics of
SK&F 86002 were compared to those of the classical inducer,
phenobarbital, and morphological features of both
SK&F 86002 and
phenobarbital induced hepatocellular
hypertrophy were quantitated. Rats were administered either
SK&F 86002 (6, 18, or 60 mg/kg/day, po) or
phenobarbital (8, 24, 80 mg/kg/day, ip) for 3 or 14 consecutive days. Liver to
body weight ratio, total hepatic microsomal
protein and
cytochrome P-450 content,
ethoxycoumarin-O-deethylase (ECOD) and
leukotriene B4(
LTB4) omega- and
omega-1 hydroxylase were measured. Ultrastructural morphometry of the liver from control, and high dose
SK&F 86002 (60 mg/kg/day) and
phenobarbital (80 mg/kg/day) treated rats was completed. On day 3,
phenobarbital increased liver to
body weight ratio but only at the 80 mg/kg/day dosage; microsomal
protein content was unchanged. ECOD activity increased in a dose-dependent fashion.
LTB4 omega- and
omega-1 hydroxylase activities were unaffected. Administration of
SK&F 86002 for 3 days increased the liver to
body weight ratio at both the 18 and 60 mg/kg/day dosage; microsomal
protein content was unchanged. ECOD activity was significantly increased by the 60 mg/kg/day dosages of
SK&F 86002. On day 14,
phenobarbital increased the liver to
body weight ratio and microsomal
protein content but again only at the 80 mg/kg/day dosage.
Cytochrome P-450 content was increased by all dosages.(ABSTRACT TRUNCATED AT 250 WORDS)